Saikawa Y, Kubota T, Kuo T H, Kase S, Furukawa T, Tanino H, Ishibiki K, Kitajima M
Department of Surgery, School of Medicine, Keio University, Tokyo, Japan.
J Surg Oncol. 1993 Oct;54(2):98-102. doi: 10.1002/jso.2930540209.
The synergistic antitumor activity of mitomycin C (MMC) and cisplatin (DDP) against the gastric cancer cell lines MKN-28 and MKN-45 was assessed in vitro using the MTT assay. The synergism of the two agents was evaluated in terms of the interaction index (I.I.). The sequence of MMC followed by DDP showed higher antitumor activity than the reverse sequence against MKN-28 and MKN-45, and the intracellular concentration of platinum was significantly increased in MKN-45 by preincubation with MMC, suggesting that MMC modulates cellular permeability to DDP or the ability of DDP to intercalate DNA. Since these two antitumor agents show different types of toxicity clinically, i.e., myelotoxicity by MMC and nephrotoxicity by DDP, this combination chemotherapy could be advantageous by providing synergistic antitumor activity without increased toxicity.
采用MTT法在体外评估丝裂霉素C(MMC)和顺铂(DDP)对胃癌细胞系MKN - 28和MKN - 45的协同抗肿瘤活性。根据相互作用指数(I.I.)评估这两种药物的协同作用。MMC后接DDP的给药顺序比相反顺序对MKN - 28和MKN - 45显示出更高的抗肿瘤活性,并且通过MMC预孵育,MKN - 45中的铂细胞内浓度显著增加,这表明MMC调节细胞对DDP的通透性或DDP嵌入DNA的能力。由于这两种抗肿瘤药物在临床上表现出不同类型的毒性,即MMC引起的骨髓毒性和DDP引起的肾毒性,这种联合化疗在不增加毒性的情况下提供协同抗肿瘤活性可能具有优势。